Seoul Central District Court fined Lee for being administered propofol, a sedative used in anaesthesia, multiple times between 2015-2020, Yonhap said.
Under South Korean law, the recipient of a controlled substance deemed to have been administered illegally is liable for prosecution, as well as those who administered the drug.
Lee has kept a low public profile since his parole in August from a bribery and embezzlement conviction in January. He remains on trial accused of stock-price manipulation and accounting fraud related to the $8 billion merger of two Samsung (KS:005930) firms in 2015.
($1 = 1,177.2300 won)